Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg £68
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  3. Milanovic M, et al. 2021. Cancer Res. 81:426. PubMed
  4. Aimaitijiang A, et al. 2022. Genes Cells. 27:25. PubMed
  5. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  6. Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed
  7. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  8. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  9. Chowdhury S, et al. 2022. Cancer Res. 82:2640. PubMed
  10. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  11. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  12. Deng P, et al. 2022. J Clin Invest. 132: . PubMed
  13. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  14. Li J, et al. 2022. Front Immunol. 13:1043484. PubMed
  15. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  16. Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed
  17. Ding L, et al. 2023. J Clin Invest. 133: . PubMed
  18. Choi H, et al. 2023. J Nanobiotechnology. 21:5. PubMed
  19. Wang L, et al. 2022. Nutrients. 15: . PubMed
  20. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  21. Elliot TAE, et al. 2022. Discov Immunol. 1:kyac009. PubMed
  22. Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed
  23. Wang J, et al. 2023. Inflamm Regen. 43:12. PubMed
  24. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  25. Milanovic M, et al. 2021. J Immunol. 206:1228. PubMed
  26. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  27. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  28. Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed
  29. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  30. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  31. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  32. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  33. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  34. Liu J, et al. 2019. Immunity. 50:600. PubMed
  35. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  36. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  37. Lee KM, et al. 2022. Cancer Immunol Res. 10:829. PubMed
  38. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  39. Alghamri MS, et al. 2022. ACS Nano. 16:8729. PubMed
  40. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  41. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  42. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  43. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  44. Ma X, et al. 2023. Nat Commun. 14:1606. PubMed
  45. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  46. Li D, et al. 2023. Ann Med. 55:2189295. PubMed
  47. Bhatia V, et al. 2023. Nat Commun. 14:2041. PubMed
  48. Chen F, et al. 2023. Acta Biomater. 164:387. PubMed
  49. Li Y, et al. 2023. Front Cell Infect Microbiol. 13:1117230. PubMed
  50. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  51. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  52. Park HJ, et al. 2023. NPJ Vaccines. 8:84. PubMed
  53. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  54. Pagano G, et al. 2023. Haematologica. . PubMed
  55. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  56. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  57. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  58. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  59. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  60. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  61. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  62. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  63. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  64. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  65. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  66. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  67. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  68. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  69. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  70. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  71. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  72. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  73. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  74. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  75. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  76. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  77. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  78. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  79. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  80. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  81. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  82. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  83. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  84. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  85. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  86. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  87. Morales D, et al. 2015. J Virol. 89:337. PubMed
  88. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  89. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  90. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  91. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  92. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  93. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  94. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  95. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  96. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  97. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  98. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  99. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  100. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  101. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  102. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  103. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  104. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  105. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  106. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  107. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  108. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  109. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  110. Yu Y, et al. 2022. Nat Commun. 13:6357. PubMed
  111. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  112. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  113. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  114. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  115. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  116. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  117. Wu J, et al. 2020. Immunity. 53:115. PubMed
  118. Köchl R, et al. 2020. Elife. 9:00. PubMed
  119. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  120. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  121. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  122. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  123. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  124. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  125. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  126. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  127. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  128. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  129. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  130. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  131. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  132. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  133. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  134. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  135. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  136. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  137. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  138. Yang J, et al. 2020. Nature. 586:572. PubMed
  139. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  140. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  141. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  142. Wan X, et al. 2018. Nature. 560:107. PubMed
  143. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  144. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  145. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  146. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  147. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  148. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  149. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  150. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  151. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  152. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  153. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  154. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  155. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  156. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  157. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  158. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  159. Du J, et al. 2018. AMB Express. 8:158. PubMed
  160. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  161. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  162. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  163. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  164. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  165. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  166. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  167. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  168. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  169. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  170. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  171. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  172. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  173. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  174. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  175. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  176. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  177. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  178. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  179. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  180. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  181. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  182. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  183. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  184. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  185. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  186. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  187. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  188. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  189. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  190. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  191. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  192. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  193. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  194. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  195. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  196. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  197. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  198. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  199. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  200. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  201. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  202. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  203. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  204. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  205. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  206. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  207. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  208. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  209. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  210. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  211. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  212. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  213. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  214. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  215. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  216. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  217. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  218. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  219. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  220. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  221. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  222. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  223. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  224. Li H, et al. 2022. iScience. 25:104481. PubMed
  225. Wang X, et al. 2022. Elife. 11:. PubMed
  226. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  227. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  228. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  229. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  230. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  231. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  232. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  233. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  234. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  235. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  236. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  237. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  238. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  239. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  240. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  241. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  242. Lee S, et al. 2021. Autophagy. 18:1062. PubMed
  243. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  244. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  245. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  246. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  247. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  248. Xie L, et al. 2020. Infect Immun. :88. PubMed
  249. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  250. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  251. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  252. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312744 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account